Your browser doesn't support javascript.
loading
HER2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosis.
Bruce, Shaina F; Wu, Sharon; Ribeiro, Jennifer R; Farrell, Alex; Oberley, Matthew J; Winer, Ira; Erickson, Britt K; Klc, Tenley; Jones, Nathaniel L; Thaker, Premal H; Powell, Matthew A.
Afiliación
  • Bruce SF; Washington University School of Medicine, St. Louis, MO, USA. Electronic address: brucesf@wustl.edu.
  • Wu S; Caris Life Sciences, Phoenix, AZ, USA.
  • Ribeiro JR; Caris Life Sciences, Phoenix, AZ, USA.
  • Farrell A; Caris Life Sciences, Phoenix, AZ, USA.
  • Oberley MJ; Caris Life Sciences, Phoenix, AZ, USA.
  • Winer I; Karmanos Cancer Institute and Wayne State University, Detroit, MI, USA.
  • Erickson BK; University of Minnesota, Division of Gynecologic Oncology, Minneapolis, MN, USA.
  • Klc T; University of Minnesota, Division of Gynecologic Oncology, Minneapolis, MN, USA.
  • Jones NL; Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA.
  • Thaker PH; Washington University School of Medicine, St. Louis, MO, USA.
  • Powell MA; Washington University School of Medicine, St. Louis, MO, USA.
Gynecol Oncol ; 172: 98-105, 2023 05.
Article en En | MEDLINE | ID: mdl-37003074

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Uterinas / Neoplasias Endometriales / Carcinoma Endometrioide Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Gynecol Oncol Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Uterinas / Neoplasias Endometriales / Carcinoma Endometrioide Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Gynecol Oncol Año: 2023 Tipo del documento: Article